Description

B7-33 Research Topics:

1. 1. Anti-fibrotic:

      Reduces fibrotic tissue formation and collagen deposition by selectively activating the ERK1/2 pathway. [1]

   2. Cardioprotective:

      Preserves cardiac function and reduces infarct size and remodeling after myocardial injury. [2]

   3. Enhanced Stability:

      Lipidated versions show improved serum half-life while maintaining RXFP1 activity. [3]

   4. Reduced Side Effects:

      Avoids cAMP-related hormonal effects, offering targeted activity with fewer systemic responses. [1]

Reference Citation:

1. Hossain et al., 2016 – A single‑chain derivative of the relaxin hormone is a functionally selective agonist of the G‑protein coupled receptor, RXFP1. Reports the design of B7‑33, a single‑chain relaxin B‑chain analogue that binds RXFP1 and selectively activates the ERK1/2 (pERK) signaling pathway without stimulating cAMP. Demonstrates potent anti‑fibrotic and organ‑protective effects in multiple rodent disease models. Pubs.rsc
2. Teja Devarakonda et al. (2020) – B7‑33 attenuates myocardial infarction–related adverse cardiac remodeling in mice Shows cardioprotective benefits of B7‑33 in a mouse ischemia‑reperfusion model: reduced infarct size, preserved cardiac function, decreased fibrosis and ER stress via ERK signaling pmc.ncbi.nlm.nih.gov+1emorywheel.com
3. Zhang et al., 2023 – A lipidated single‑B‑chain derivative of relaxin exhibits improved in vitro serum half‑life
   Describes enhancing the pharmacokinetic profile of B7‑33 by conjugating fatty acids, boosting its serum stability from ~6 min to ~60 min, while retaining RXFP1 binding and activity pubmed.ncbi.nlm.nih.gov+1emorywheel.com